Website: N/A
Stock Symbol: NASDAQ: DARA
Market Value: N/A (in millions)

We use the term “Point” to describe our business prior to the merger transaction between Point Therapeutics, Inc. (“Point”) and DARA BioSciences, Inc. (“DARA”) completed on February 12, 2008. From May 1997 to May 2007, Point developed a family of dipeptidyl peptidase inhibitors for oncology and type 2 diabetes.

Point studied its lead product candidate, talabostat, in a number of human clinical trials as a potential therapy in late-stage cancers. In May 2007, interim clinical results caused Point’s Independent Data Monitoring Committee to recommend stopping Point’s most advanced clinical trials, its two Phase 3 talabostat studies as a potential treatment for patients in advanced non-small cell lung cancer. Subsequently, the talabostat clinical development program was put on clinical hold by the FDA.